ABLYNX Win Patent Opposition Case - Gilde Healthcare

ABLYNX Win Patent Opposition Case

11. Februar 2010

GHENT, Belgium – Ablynx [Euronext Brussels: ABLX] today announced that it has been successful in the opposition that it had filed in 2007 against the European Patent 1 517 921, which was granted in 2006 to Domantis (now a member of the GlaxoSmithKline group of companies). As a result, the Opposition Division of the European Patent Office yesterday decided to revoke the Domantis patent in full. If this decision becomes final, all the claims of this patent as originally granted will be deemed to have never existed.
 
The European Patent 1 517 921 related to one specific technique for the half-life extension of immunoglobulin single variable domains. Without this patent, the techniques described in this patent can be applied by Ablynx and its partners in Europe for their internal and partnered programmes without Domantis being able to assert this patent against such activities in Europe.
 
Edwin Moses, CEO and Chairman of Ablynx, commented:

“This is the result that we always anticipated. From all the evidence available to us, we strongly believe that our current half-life extension technologies currently outperform those of GSK/Domantis, and that once this patent has been finally revoked, we and our partners can be confident that we will have yet another half-life extension technology available to us that we can use without being encumbered by third party patent rights. This is in addition to our own proprietary NExpedite® technology, which is showing ever greater promise. All this will allow us to even further exploit our already well established technical lead over GSK/Domantis, which is for example evidenced by our recent advances in making Nanobodies against some complex targets and classes of targets (such as G-Protein Coupled Receptors (GPCRs), ion channels and viruses). Also, our Nanobody technology has extensive patent protection and four Nanobody based products are currently in clinical trials.”

Domantis is expected to appeal the decision by the Opposition Division, but Ablynx sees no reason why the arguments that were successful for Ablynx in the opposition proceedings should not be equally successful in appeal. Under the provisions of the European Patent Convention, an appeal filed by Domantis will suspend the decision of the Opposition Division.

Gilde Healthcare Adcendo Completes $135 Million Series B to Advance First- in-class ADC Pipeline

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support...
25. November 2024

Gilde Healthcare portfolio company Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04 at ACR Convergence 2024

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis, is presenting the results from its positive Phase II trial of LEVI-04 at the American College of Rheumatology's annual...
14. November 2024

Gilde Healthcare company Noema Pharma Announces First Patients Dosed in Phase 2b Study for Tourette Syndrome

Phase 2b study will evaluate the safety and efficacy of gemlapodect (NOE-105) in patients with Tourette syndrome Noema Pharma AG, a clinical-stage neuroscience-based company, today announced the first patients have been dosed in a global...
30. Oktober 2024